Chemoradiotherapy Combined With Serplulimab for Locally Advanced Cervical Cancer: A Prospective, Multicenter, Randomized, Phase II Clinical Trial
The ongoing Phase II clinical trial investigates the combination of serplulimab, a PD-1 inhibitor, with chemoradiotherapy in patients with locally advanced cervical cancer. This indication represents a significant market opportunity, given the increasing incidence of cervical cancer globally and the limited treatment options for advanced stages. The trial's focus on progression-free survival (PFS) as a primary endpoint aligns with current oncology trends prioritizing durable responses. Competitive implications include positioning serplulimab against established therapies and emerging immunotherapies, necessitating a robust efficacy profile to capture market share. Diligence should focus on the trial's recruitment pace and safety profile, as these factors will influence future regulatory submissions and market access strategies.
Indication: Cervical Cancer
Modality: small molecule
Target: PD-1 (Programmed Cell Death Protein 1)
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1 (Programmed Cell Death Protein 1)
View original source fields
Condition raw: Cervical Cancer
Condition normalized: Cervical Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PD-1 (Programmed Cell Death Protein 1)
Target normalized: PD-1 (Programmed Cell Death Protein 1)